Applications of machine learning for immunophenotypic measurable residual disease assessment in acute myeloid leukemia
HemaSphere · 2025-05 · 9 (5)
DOI: 10.1002/hem3.70138 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift HemaSphere, online erschienen am 21.05.2025. Verfasst von Tim R Mocking und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam The Netherlands. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Immunophenotypic detection and quantification of residual leukemic cells by multiparameter flow cytometry is increasingly adopted in the clinical practice of acute myeloid leukemia (AML) to assess measurable residual disease (MRD). However, MRD levels quantified by manual gating analysis can differ based on differences in gating strategy between trained operators and clinical centers. Manual gating requires extensive training, is time‐consuming in daily practice, and faces a significant hurdle in analyzing data from next‐generation cytometry platforms. To address these challenges, several computational approaches involving machine learning and artificial intelligence algorithms have been proposed to automate or aid the assessment of MRD. However, the immunophenotypic variability between patients and the relatively low proportions of residual leukemic cells in AML challenge most algorithms and require innovative approaches. This review provides an overview of recent efforts in using computational methods for immunophenotypic AML‐MRD assessment. We first explain the technical and conceptual background of the different algorithms that have been explored. Next, we discuss their strengths and limitations in the disease‐specific context of AML. Finally, we highlight how computational approaches offer a unique opportunity to standardize or even outperform current manual gating analyses, and ultimately, improve the treatment of AML patients.
Autor:innen und Institutionen
- Department of Hematology, Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam The Netherlands.
- Cancer Center Amsterdam Imaging and Biomarkers Amsterdam The Netherlands.
ORCID-Profile: Tim R Mocking, Arjan A van de Loosdrecht, Jacqueline Cloos, Costa Bachas
Zitieren
APA
Mocking, T. R., van de Loosdrecht, A. A., Cloos, J., & Bachas, C. (2025). Applications of machine learning for immunophenotypic measurable residual disease assessment in acute myeloid leukemia. HemaSphere, 9(5). https://doi.org/10.1002/hem3.70138
Vancouver
Mocking TR, van de Loosdrecht AA, Cloos J, Bachas C. Applications of machine learning for immunophenotypic measurable residual disease assessment in acute myeloid leukemia. HemaSphere. 2025;9(5). doi:10.1002/hem3.70138
BibTeX
@article{Mocking2025,
author = {Mocking, Tim R and van de Loosdrecht, Arjan A and Cloos, Jacqueline and Bachas, Costa},
title = {Applications of machine learning for immunophenotypic measurable residual disease assessment in acute myeloid leukemia},
journal = {HemaSphere},
year = {2025},
volume = {9},
number = {5},
doi = {10.1002/hem3.70138}
}
EUVIMED